Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Open-label, Phase 3 Long-term Safety Study of Topically Applied Sofpironium Bromide (BBI-4000) Gel, 5% and 15% in Subjects With Axillary Hyperhidrosis

Next Previous
Trial Profile

A Multicenter, Randomized, Open-label, Phase 3 Long-term Safety Study of Topically Applied Sofpironium Bromide (BBI-4000) Gel, 5% and 15% in Subjects With Axillary Hyperhidrosis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sofpironium bromide (Primary)
  • Indications Hyperhidrosis
  • Focus Adverse reactions; Registrational
  • Acronyms ARGYLE
  • Sponsors Botanix Pharmaceuticals

    • Most Recent Events

    • 23 Apr 2021 According to a Brickell Biotech Inc media release,190 patients completed the full study duration of 52 weeks.
    • 23 Apr 2021 Results presented in a Brickell Biotech Inc Media Release.
    • 23 Apr 2021 According to a Brickell Biotech Inc media release, data were presented at the American Academy of Dermatology (AAD) 2021 Virtual Meeting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top